Short answer: A liposomal compounding pharmacy prepares oral or topical formulations in which the active ingredient is enclosed inside phospholipid vesicles rather than dissolved in a simple base. A prescriber chooses liposomal delivery when an active has poor oral bioavailability due to rapid first-pass metabolism or low solubility, and published human trials show liposomal vehicles can raise plasma exposure for vitamins, minerals and polyphenols compared with non-liposomal forms. Every preparation is compounded as a non-sterile capsule, liquid, cream, gel, tonic or serum for a named patient on a doctor’s prescription under Good Compounding Practice (GCP).
What liposomal compounding means in a non-sterile pharmacy
Liposomal compounding is the preparation of a compounded formulation in which one or more active ingredients are encapsulated within lipid bilayer vesicles — microscopic spheres whose outer shell is built from phospholipids. These vesicles, typically in the nanometre-to-micrometre range, surround the active compound and carry it through a portion of the digestive tract or across a mucosal surface before releasing it. The concept originates from pharmaceutical delivery science, where liposomal vehicles have been studied for decades as a means of protecting compounds that are poorly absorbed, rapidly metabolised, or unstable in the gut environment.
In a non-sterile compounding pharmacy, liposomal preparations are prepared for oral or topical use — not for injection. The dosage forms a non-sterile compounding pharmacy prepares include capsules, liquids (including oral liquids and suspensions), creams, gels, tonics and serums, and each of these may be prepared in a liposomal or an ordinary form. A liposomal oral liquid, for example, suspends the active inside phospholipid vesicles dispersed in an aqueous vehicle; a liposomal cream or gel applies the same encapsulation principle to a topical base. The pharmacy prepares each formulation to a prescriber’s specification for one named patient, under Good Compounding Practice (GCP).
How liposomal encapsulation works
The structural basis of liposomal delivery is the phospholipid bilayer. Phospholipids are amphiphilic molecules: one end is hydrophilic (water-attracting) and the other is lipophilic (fat-attracting). When dispersed in water under the right conditions, they self-assemble into closed vesicles — a spherical bilayer with an aqueous core. Hydrophilic actives can be entrapped in the core; lipophilic actives can be incorporated into the bilayer itself.
The pharmaceutical rationale for this structure rests on three mechanisms:
- Protection from first-pass metabolism: The phospholipid shell can shield the active from enzymes in the intestinal wall and liver that would otherwise conjugate or degrade it before it reaches systemic circulation. This is the central problem for polyphenols such as curcumin and resveratrol, whose free parent fraction after oral administration is typically very low.
- Enhanced solubility: Compounds with poor aqueous solubility can be carried inside the lipophilic portion of the bilayer, improving their presentation to the absorptive surface of the gut.
- Membrane fusion: Because the phospholipid bilayer resembles the body’s own cell membranes, liposomal vesicles may fuse with or be taken up by enterocytes more readily than a free compound in solution.
These mechanisms are not guarantees. The extent to which a liposomal vehicle improves delivery depends on the active ingredient, the vesicle size and composition, the route of administration, and the individual patient’s gastrointestinal physiology. The evidence base — discussed below — is ingredient-specific, not universal.
When a prescriber would choose a liposomal preparation over a standard form
The decision to specify a liposomal vehicle rather than a standard compounded formulation is a clinical and pharmaceutical judgement, not a default upgrade. A prescriber considers liposomal delivery when the active ingredient has a documented bioavailability problem that the liposomal vehicle is designed to address. The following scenarios are the most common:
Actives with extensive first-pass conjugation
Polyphenols — including curcumin, resveratrol and quercetin — are absorbed from the gut but rapidly converted to glucuronide and sulfate metabolites by the intestinal wall and liver. The circulating free fraction is typically a small percentage of the oral dose. A liposomal vehicle may protect a portion of the dose from this first-pass conversion, potentially increasing the fraction that reaches systemic circulation as the parent molecule. A randomised, double-blind clinical trial of a novel double-layered nano-liposomal curcumin formulation reported enhanced oral bioavailability compared with a standard curcumin preparation (Kim et al., Scientific Reports, 2026; PMID 42225688). A randomised crossover trial of quercetin delivered in a food-grade lecithin phytosome demonstrated improved oral absorption compared with unformulated quercetin (Riva et al., European Journal of Drug Metabolism and Pharmacokinetics, 2019; PMID 30328058).
Actives with low aqueous solubility
Compounds that dissolve poorly in the gut lumen may benefit from a lipophilic carrier that presents them to the absorptive epithelium in a more bioavailable form. A randomised crossover trial of liposomal mineral absorption found that a liposomal delivery system influenced the absorption profile of minerals compared with a non-liposomal reference (Tinsley et al., Nutrients, 2022; PMID 36014827). A randomised controlled trial of a next-generation liposomal coenzyme Q10 formulation reported improved oral absorption relative to a conventional form (Amalraj et al., Food & Function, 2026; PMID 41582714).
Vitamins where peak plasma concentration matters
For vitamin C, a randomised controlled trial comparing liposomal and non-liposomal ascorbic acid found that the liposomal form produced higher plasma vitamin C levels than the non-liposomal form (Gopi et al., Journal of Liposome Research, 2021; PMID 32901526). A double-blind, placebo-controlled, randomised trial reported that liposomal delivery enhanced absorption of vitamin C into both plasma and leukocytes compared with a non-liposomal preparation (Purpura et al., European Journal of Nutrition, 2024; PMID 39237620). These findings are relevant when a prescriber’s clinical intent is to achieve a higher circulating concentration of the vitamin than a standard oral preparation reliably delivers.
When a standard form remains appropriate
For actives that are well absorbed orally, stable in the gut, and available at therapeutic strength in a standard capsule or liquid, a liposomal vehicle adds formulation complexity without a clear pharmacokinetic advantage. A prescriber who is compounding a simple vitamin, mineral or hormone at a strength and form that the patient tolerates may have no reason to specify liposomal delivery. The decision is ingredient-specific: the question is whether the active’s documented absorption profile justifies the liposomal vehicle, not whether liposomal is inherently superior.
What the evidence shows — and what it does not
The human clinical evidence for liposomal delivery is strongest for specific actives — vitamin C, curcumin, quercetin, coenzyme Q10 and certain minerals — where randomised trials have measured pharmacokinetic differences between liposomal and non-liposomal forms. The evidence describes the active ingredient and the specific formulation studied, not any individual compounded preparation. A liposomal preparation compounded in a non-sterile pharmacy is not the same formulation as the one used in a published trial, and trial results cannot be extrapolated to assume equivalent performance.
Where the evidence is thin or absent for a particular active, a prescriber should treat the liposomal option as a formulation choice based on mechanistic rationale rather than confirmed clinical data. Honest acknowledgement of this limitation is part of responsible prescribing. The compounding pharmacy can advise on whether a liposomal vehicle is technically feasible for a given active and what stability and compatibility constraints apply.
What makes a liposomal compounding pharmacy distinct
Not every compounding pharmacy prepares liposomal formulations. The preparation of a liposomal vehicle requires specific knowledge of phospholipid chemistry, vesicle formation techniques, and the stability constraints of lipid-based systems. A compounding pharmacy that offers liposomal delivery as a formulation option brings several distinct capabilities:
- Formulation expertise in lipid systems: The pharmacy must select appropriate phospholipids, determine vesicle size and composition, and confirm that the active is compatible with the lipid vehicle and stable over the assigned beyond-use date.
- Non-sterile scope, clearly defined: Liposomal compounding in this context is non-sterile — oral liquids, capsules, creams, gels, tonics and serums. A pharmacy that is transparent about its non-sterile scope is being honest about what it can and cannot prepare.
- Named-patient, prescription-only operation: Every liposomal preparation is made for one individual on a doctor’s prescription under Good Compounding Practice (GCP). This is the regulatory and clinical framework that distinguishes patient-specific compounding from mass-market supplement manufacturing.
- Prescriber-to-pharmacist collaboration: The formulation decision — whether to specify a liposomal vehicle, which dosage form to use, which strength and which excipients — is a collaborative discussion between the prescriber and the pharmacy. The pharmacy can advise on feasibility, stability and compatibility before the formulation is finalised.
Across its published materials, Lynnity Pharma describes itself as a non-sterile compounding pharmacy in Kuala Lumpur serving the Klang Valley, with enquiries also coming from Singapore. The pharmacy operates on a prescription-only basis under Good Compounding Practice, and liposomal delivery is among the formulation options discussed in its prescriber-facing content.
Discussing a liposomal preparation with Lynnity
Lynnity Pharma prepares non-sterile compounded formulations in capsules, liquids (including oral liquids and suspensions), creams, gels, tonics and serums — each available in a liposomal or an ordinary form — for a named patient on a doctor’s prescription under Good Compounding Practice. A prescriber considering a liposomal vehicle for a specific active can include this preference in the formulation brief sent with the prescription, and the pharmacy can advise on whether the liposomal form is technically feasible for that active, what stability constraints apply, and which dosage form best suits the patient’s needs.
For prescribers already referring patients for compounded preparations, the same prescription and formulation brief process applies whether the requested form is liposomal or standard. The pharmacy confirms the dosage form, strength, vehicle and excipient requirements before preparation. Where a prescriber is also considering a related preparation — a standard compounded capsule or liquid for the same active, or a topical cream or gel for local delivery — the pharmacy can prepare either form on the same prescription channel.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632)
Frequently asked questions
What is a liposomal compounding pharmacy?
A liposomal compounding pharmacy is a non-sterile compounding pharmacy that prepares formulations in which the active ingredient is encapsulated within phospholipid vesicles. The dosage forms prepared — capsules, liquids, creams, gels, tonics and serums — may be specified in a liposomal or an ordinary form. Every preparation is made for a named patient on a doctor’s prescription under Good Compounding Practice.
When should a prescriber choose a liposomal formulation over a standard compounded form?
A prescriber considers liposomal delivery when the active ingredient has a documented bioavailability limitation — extensive first-pass conjugation, poor aqueous solubility, or low circulating free fraction — that the liposomal vehicle is designed to address. For actives that are well absorbed and stable in a standard form, a liposomal vehicle may add complexity without a clear pharmacokinetic advantage.
Is there clinical evidence that liposomal delivery improves absorption?
Randomised human trials have reported enhanced bioavailability for liposomal forms of vitamin C, curcumin, quercetin, coenzyme Q10 and certain minerals compared with non-liposomal forms. The evidence is ingredient-specific and describes the formulations studied in each trial, not any individual compounded preparation. Results cannot be extrapolated to assume equivalent performance for a different compounded formulation.
Can a liposomal preparation be compounded for topical use?
Yes. Liposomal encapsulation can be applied to topical dosage forms — creams, gels and serums — as well as to oral liquids and capsules. The phospholipid vesicle may carry the active to the skin or mucosal surface and release it at the target site. The feasibility and stability of a liposomal topical preparation depend on the active ingredient and the vehicle, and the pharmacy can advise on this during the formulation discussion.
How does a prescriber refer a patient for a liposomal compounded preparation?
The referral process is the same as for any compounded formulation: write a named-patient prescription specifying the active, strength and dosage form, and include a formulation brief noting the preference for a liposomal vehicle. The pharmacy confirms feasibility, stability and excipient compatibility before preparation. The prescription is the legal and clinical basis for the preparation.
To discuss a patient-specific liposomal preparation — whether an oral liquid, capsule, cream, gel, tonic or serum — consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.